α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Science Translational Medicine

• Publication date

  2012-12-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scitranslmed.3004676PMID 23220632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MicroRNA-124 Is a Subventricular Zone Neuronal Fate Determinant

  2012cited by this paper
• Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.

  2012cited by this paper
• Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.

  2012cited by this paper
• Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.

  2012cited by this paper
• Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons

  2012cited by this paper
• Nurr1 Protein Is Required for N-Methyl-d-aspartic Acid (NMDA) Receptor-mediated Neuronal Survival*

  2012cited by this paper
• Parkinson's disease and α‐synuclein expression

  2011cited by this paper
• Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.

  2011cited by this paper
• Pitx3 Is a Critical Mediator of GDNF-Induced BDNF Expression in Nigrostriatal Dopaminergic Neurons

  2011cited by this paper
• Signaling of Glial Cell Line-Derived Neurotrophic Factor and Its Receptor GFR&agr;1 Induce Nurr1 and Pitx3 to Promote Survival of Grafted Midbrain-Derived Neural Stem Cells in a Rat Model of Parkinson Disease

  2011influential reference
• Repairing the parkinsonian brain with neurotrophic factors.

  2011cited by this paper
• The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS.

  2011cited by this paper
• GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

  2011cited by this paper
• Priorities in Parkinson's disease research

  2011cited by this paper
• α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.

  2011influential reference
• Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis

  2011influential reference
• α-Synuclein Negatively Regulates Protein Kinase Cδ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity

  2011cited by this paper
• Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates.

  2011cited by this paper
• Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains

  2011cited by this paper
• MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells.

  2010cited by this paper
• miR-22 Forms a Regulatory Loop in PTEN/AKT Pathway and Modulates Signaling Kinetics

  2010influential reference
• NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection

  2010influential reference
• Neurotoxic in vivo models of Parkinson's disease recent advances.

  2010cited by this paper
• α-Synuclein and dopamine at the crossroads of Parkinson's disease.

  2010cited by this paper
• Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153

  2010cited by this paper
• Characterisation of a novel NR4A2 mutation in Parkinson's disease brain.

  2009cited by this paper
• Repression of α-synuclein expression and toxicity by microRNA-7

  2009cited by this paper
• Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.

  2009cited by this paper
• Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy

  2009cited by this paper
• Nurr1 Is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons

  2009cited by this paper
• Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression

  2009cited by this paper
• Trophic factors therapy in Parkinson's disease.

  2009cited by this paper
• PI3 kinase/Akt activation mediates estrogen and IGF‐1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease

  2008influential reference
• Absolute requirement of GDNF for adult catecholaminergic neuron survival

  2008cited by this paper
• Biochemical Fractionation of Brain Tissue for Studies of Receptor Distribution and Trafficking

  2008cited by this paper
• Glutamate receptors on dopamine neurons control the persistence of cocaine seeking.

  2008cited by this paper
• Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.

  2008cited by this paper
• Accumulation of phosphorylated α‐synuclein in dopaminergic neurons of transgenic mice that express human α‐synuclein

  2007cited by this paper
• Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein.

  2007cited by this paper
• A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons

  2007cited by this paper
• Absence of Ret Signaling in Mice Causes Progressive and Late Degeneration of the Nigrostriatal System

  2007cited by this paper
• Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

  2007cited by this paper
• Extensive nuclear localization of α-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody

  2007cited by this paper
• Distribution and localization patterns of estrogen receptor‐β and insulin‐like growth factor‐1 receptors in neurons and glial cells of the female rat substantia nigra: Localization of ERβ and IGF‐1R in substantia nigra

  2007cited by this paper
• Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

  2007cited by this paper
• Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease

  2007cited by this paper
• Crossroads in GDNF therapy for Parkinson's disease

  2006cited by this paper
• Nurr1 in Parkinson's disease and related disorders

  2006cited by this paper
• RET Is Dispensable for Maintenance of Midbrain Dopaminergic Neurons in Adult Mice

  2006cited by this paper
• Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

  2006cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• Localized striatal delivery of GDNF as a treatment for Parkinson disease

  2004cited by this paper
• Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.

  2004cited by this paper
• Type 2 Diabetes in Childhood: The American Perspective

  2003cited by this paper
• Nuclear Localization of α-Synuclein and Its Interaction with Histones†

  2003cited by this paper
• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

  2003cited by this paper
• Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

  2003cited by this paper
• Mutations in NR4A2 associated with familial Parkinson disease

  2003cited by this paper
• Nuclear localization of alpha-synuclein and its interaction with histones.

  2003cited by this paper
• Production methods for gene transfer vectors based on adeno-associated virus serotypes.

  2002cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Is CREB a key to neuronal survival?

  2000cited by this paper
• Reduced Nurrl Expression Increases the Vulnerability of Mesencephalic Dopamine Neurons to MPTP‐Induced Injury

  1999cited by this paper
• Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

  1999cited by this paper
• Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons.

  1998cited by this paper
• Dopamine neuron agenesis in Nurr1-deficient mice.

  1997cited by this paper
• Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult.

  1995cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper

• Mechanistic insights into the role of nuclear receptor related-1 protein in Parkinson's disease.

  2026cites this paper
• The role of GDNF in neurodegenerative pathologies

  2026cites this paper
• The Involvement of Ceramide, Sphingosine-1-Phosphate and Ganglioside GM1 in Regulating Some Nervous System Functions

  2025cites this paper
• Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson's disease: From pathogenesis to potential therapeutic strategies.

  2025cites this paper
• Nurr1 modulators – a patent review (2019–present)

  2025cites this paper
• Dual Nurr1/RXR agonism of valerenic acid and synthetic mimetics enables dimer-selective Nurr1 modulation

  2025cites this paper
• Rapamycin exerts neuroprotective effects by inhibiting FKBP12 instead of mTORC1 in the mouse model of Parkinson's disease.

  2025cites this paper
• Structural and mechanistic profiling of Nurr1 modulation by vidofludimus enables structure-guided ligand design

  2025cites this paper
• Integrating artificial intelligence and optogenetics for Parkinson’s disease diagnosis and therapeutics in male mice

  2025cites this paper
• The multiple mechanisms of NR4A2 in neurological disorders and advances in targeted therapy research.

  2025cites this paper
• Human Pluripotent Stem Cell-Based Therapies for Parkinson’s Disease: Challenges and Potential Solutions

  2025cites this paper
• A Nurr1 agonist derived from the natural ligand DHI induces neuroprotective gene expression

  2025cites this paper
• Biology of RET receptor and its ligands: focus on the nervous system.

  2025cites this paper
• GDNF reduces fibril-induced early-stage alpha-synuclein pathology after delivery of 20S proteasome inhibitor lactacystin.

  2025cites this paper
• Structural Perspective of NR4A Nuclear Receptor Family and Their Potential Endogenous Ligands.

  2024cites this paper
• Investigating the Effect of an Anti-Inflammatory Drug in Determining NURR1 Expression and Thus Exploring the Progression of Parkinson's Disease.

  2024influential citation
• The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson’s Disease

  2024cites this paper
• Preparation of human astrocytes with potent therapeutic functions from human pluripotent stem cells using ventral midbrain patterning

  2024cites this paper
• Gene Therapy for Parkinson’s Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance

  2024cites this paper
• Development of Nurr1 agonists from amodiaquine by scaffold hopping and fragment growing

  2024cites this paper
• Defining a vitamin A5/X specific deficiency - vitamin A5/X as a critical dietary factor for mental health.

  2024cites this paper
• Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

  2024cites this paper
• The Use of Neurotrophic Factors as a Promising Strategy for the Treatment of Neurodegenerative Diseases (Review)

  2024cites this paper
• Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature

  2024cites this paper
• A review article on the development of dopaminergic neurons and establishment of dopaminergic neuron–based in vitro models by using immortal cell lines or stem cells to study and treat Parkinson's disease

  2024cites this paper
• Nurr1 overexpression in the primary motor cortex alleviates motor dysfunction induced by intracerebral hemorrhage in the striatum in mice

  2024cites this paper
• Post‐Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery

  2023cites this paper
• Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line–Derived Neurotrophic Factor Receptor RET in Parkinson's

  2023cites this paper
• Single-nuclei RNA sequencing uncovers heterogenous transcriptional signatures in Parkinson’s disease associated with nuclear receptor-related factor 1 defect

  2023cites this paper
• Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole

  2023cites this paper
• Unilateral rNurr1-V5 transgene expression in nigral dopaminergic neurons mitigates bilateral neuropathology and behavioral deficits in parkinsonian rats with α-synucleinopathy

  2023cites this paper
• Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.

  2023cites this paper
• Restorative cell and gene therapies for Parkinson's disease.

  2023cites this paper
• The relationship between depletion of brain GM1 ganglioside and Parkinson's disease

  2023cites this paper
• From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson’s Disease Modeling and Regenerative Therapy

  2023cites this paper
• Want of Wnt in Parkinson's disease: Could sFRP disrupt interplay between Nurr1 and Wnt signaling?

  2023cites this paper
• Long‐Term Follow‐Up of Pediatric Patients with Dyskinetic Cerebral Palsy and Deep Brain Stimulation

  2023cites this paper
• Lithium’s effects on therapeutic targets and MRI biomarkers in Parkinson’s disease: A pilot clinical trial

  2023cites this paper
• Genetic modifiers of synucleinopathies—lessons from experimental models

  2023cites this paper
• Opportunities and challenges in targeting orphan nuclear receptors.

  2023cites this paper
• An optimized Nurr1 agonist provides disease-modifying effects in Parkinson’s disease models

  2023cites this paper
• The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

  2022cites this paper
• Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.

  2022cites this paper
• Gene-Based Therapeutics for Parkinson’s Disease

  2022cites this paper
• Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson’s Disease

  2022cites this paper
• The promise of the TGF-β superfamily as a therapeutic target for Parkinson's disease.

  2022cites this paper
• Adeno-associated virus (AAV) 9-mediated gene delivery of Nurr1 and Foxa2 ameliorates symptoms and pathologies of Alzheimer disease model mice by suppressing neuro-inflammation and glial pathology

  2022cites this paper
• Transfer of neuron-derived α-synuclein to astrocytes induces neuroinflammation and blood-brain barrier damage after methamphetamine exposure: involving the regulation of nuclear receptor-associated protein 1.

  2022cites this paper
• Functional interaction between α-synuclein and Nurr1 in dopaminergic neurons.

  2022cites this paper
• Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an α-Synucleinopathy Animal Model

  2022cites this paper
• Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective

  2022cites this paper
• Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration

  2022cites this paper
• Induced Cognitive Impairments Reversed by Grafts of Neural Precursors: A Longitudinal Study in a Macaque Model of Parkinson's Disease

  2022cites this paper
• Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound?

  2022cites this paper
• LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration

  2022cites this paper
• A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System

  2022cites this paper
• Synergistic Effects of Combined Nurr1 Overexpression and Natural Inducers on the More Efficient Production of Dopaminergic Neuron-Like Cells From Stem Cells

  2022cites this paper
• LETTER TO THE EDITOR BMP5/7 protect dopaminergic neurons in an a -synuclein mouse model of Parkinson’s disease

  2021cites this paper
• Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease

  2021cites this paper
• Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1

  2021cites this paper
• Sgt1 Regulates α-Synuclein Subcellular Localization and Expression of Parkinson’s Disease Related Genes, PINK1 and PARK9

  2021cites this paper
• Striatal dopaminergic neurons as a potential target for GDNF based ischemic stroke therapy

  2021cites this paper
• NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson’s Disease

  2021cites this paper
• α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks

  2021cites this paper
• Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy

  2021cites this paper
• Nurr1 downregulation is caused by CREB inactivation in a Parkinson's disease mouse model.

  2021cites this paper
• Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice

  2021cites this paper
• Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.

  2021cites this paper
• Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic

  2021cites this paper
• Nurr1 repression mediates cardinal features of Parkinson’s disease in α-synuclein transgenic mice

  2021cites this paper
• GDNF Therapy: Can We Make It Work?

  2021cites this paper
• Pramipexole attenuates 6-OHDA-induced Parkinson’s disease by mediating the Nurr1/NF-κB pathway

  2021cites this paper
• Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

  2021influential citation
• Therapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases

  2021cites this paper
• Gene-based therapies for neurodegenerative diseases

  2021cites this paper
• Evaluating Novel RXR Agonists That Induce ApoE and Tyrosine Hydroxylase in Cultured Human Glioblastoma Cells.

  2021cites this paper
• The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson’s disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway

  2021cites this paper
• Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: NSCs as a stable source for PD treatment.

  2021cites this paper
• Reply: Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease and BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson's disease.

  2020cites this paper
• α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription

  2020cites this paper
• Nurr1Cd11bcre conditional knockout mice display inflammatory injury to nigrostriatal dopaminergic neurons.

  2020cites this paper
• The Future of GDNF in Parkinson's Disease

  2020cites this paper
• BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson’s disease

  2020cites this paper
• Gene replacement therapy provides benefit in an adult mouse model of Leigh syndrome

  2020cites this paper
• Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease.

  2020cites this paper
• A long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease.

  2020cites this paper
• Protein kinase CK2 alpha prime and alpha-synuclein constitute a key regulatory pathway in Huntington’s disease

  2020cites this paper
• Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?

  2020cites this paper
• GDNF/RET signaling in dopamine neurons in vivo

  2020cites this paper
• From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein

  2020cites this paper
• Optogenetic delivery of trophic signals in a genetic model of Parkinson’s disease

  2020cites this paper
• Can Growth Factors Cure Parkinson's Disease?

  2020cites this paper
• Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies

  2020cites this paper
• Transfer of pathological α-synuclein from neurons to astrocytes via exosomes causes inflammatory responses after METH exposure.

  2020cites this paper
• Impact of α-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized α-synuclein rat model of PD

  2020cites this paper
• Animal Models of Parkinson’s Disease: Are They Useful or Not?

  2020cites this paper
• Mesencephalic astrocyte-derived neurotrophic factor: A treatment option for parkinson's disease.

  2020cites this paper
• Alpha synuclein deficiency increases CD4+ T‐cells pro‐inflammatory profile in a Nurr1‐dependent manner

  2020cites this paper
• Gene Therapy in the Management of Parkinson's Disease: Potential of GDNF as a Promising Therapeutic Strategy.

  2020cites this paper
• CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease

  2020cites this paper